A Phase 1/2 Study of the Oral TRK Inhibitor LOXO101 (Larotrectinib) in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors
Phase of Trial: Phase I/II
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Larotrectinib (Primary) ; Larotrectinib (Primary)
- Indications CNS cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms SCOUT
- Sponsors Loxo Oncology
- 12 Jul 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
- 12 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2019.
- 06 Jun 2017 Results (data cut off: 31 Jan 2017, n=55) from NCT02122913, NCT02637687 and NCT02576431 studies, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History